Eli Lilly enters into strategic partnership on metabolic diseases with Regor Therapeutics

Novo Nordisk competitor Eli Lilly has announced a collaboration with Regor Therapeutics within metabolic diseases such as diabetes and obesity.

Photo: Vincent Kessler/Reuters/Ritzau Scanpix

US-based Eli Lilly and Regor Therapeutics Group have entered into a development collaboration and licensing agreement to discover, develop and commercialize new therapies within metabolic diseases like diabetes and obesity.

As part of the deal, Eli Lilly will have the option to license Regor's technology and discoveries. Eli Lilly will then be responsible for the clinical development, production and commercialization on a global scale, excluding China, Macau, Hong Kong and Taiwan, where Regor will retain the rights.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs